NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 276)
Posted On: 04/11/2018 5:29:44 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces New Notice of Allowance from US Patent and Trademark Office
Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has received another new Notice of Allowance from the United States Patent and Trademark Office providing claims that protect processes for making specific compositions of matter for enhanced cannabinoid delivery utilizing its DehydraTECH™ technology. This update comes on the heels of the company’s March 22, 2018, announcement of its reception of an additional Notice of Allowance for the compositions of matter. These two Notices of Allowance are expected to become Lexaria’s third and fourth granted patents in the United States. In recent months, Lexaria’s IP portfolio related to its DehydraTECH™ platform has expanded greatly, and it currently consists of a wide variety of patent families encompassing multiple applications. Existing patent applications span compositions and related methods of manufacture and use for Lexaria’s DehydraTECH™ technology with a broad range of lipophilic active substances in foods, beverages and nutritional supplements, as well as in topical preparations and pharmaceutical dosage forms.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has received another new Notice of Allowance from the United States Patent and Trademark Office providing claims that protect processes for making specific compositions of matter for enhanced cannabinoid delivery utilizing its DehydraTECH™ technology. This update comes on the heels of the company’s March 22, 2018, announcement of its reception of an additional Notice of Allowance for the compositions of matter. These two Notices of Allowance are expected to become Lexaria’s third and fourth granted patents in the United States. In recent months, Lexaria’s IP portfolio related to its DehydraTECH™ platform has expanded greatly, and it currently consists of a wide variety of patent families encompassing multiple applications. Existing patent applications span compositions and related methods of manufacture and use for Lexaria’s DehydraTECH™ technology with a broad range of lipophilic active substances in foods, beverages and nutritional supplements, as well as in topical preparations and pharmaceutical dosage forms.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼